Key facts
- Linqmed’s last known valuation is $44.8M (Apr 2025).
- It has raised $32.6M; the latest was Early Stage VC ($25.9M) in Apr 2025.
- Notable investors include Mitsubishi UFJ Capital, Mizuho Capital, Nissay Capital, JIC Venture Growth Investments, DBJ Capital — 24 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 24 names
- ·Watchlist + deal alerts for Linqmed
- ·The full record, as it builds
Funding rounds
No funding rounds for Linqmed are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Linqmed
Developer of radiopharmaceuticals designed to offer treatment for cancer. The company engages in the research and development of therapeutic and diagnostic drugs for cancer using 64Cu, which is a radioisotope of copper, enabling doctors to provide cancer treatments to patients.
- Sector
- Healthcare
- HQ
- Chiba, Japan
- Founded
- 2022
- Website
- linqmed.co.jp/
- Ownership
- Privately Held (backing)
Linqmed doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Linqmed shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Linqmed in its N-PORT filings yet. We sweep new filings monthly.